Chemotherapy-free treatment in non-Hodgkin lymphoma: a steep learning curve
Menés sur 11 patients atteints d'un lymphome récidivant ou réfractaire (3 patients atteints d'un lymphome à cellules du manteau et 8 patients atteints d'un lymphome folliculaire), ces deux essais de phase I évaluent la dose maximale tolérée de
The introduction of targeted agents for the treatment of non-Hodgkin lymphoma has resulted in substantial improvements in patient outcomes. In follicular lymphoma and mantle cell lymphoma, prolongation of overall survival has been demonstrated over the last several decades, attributed in part to the introduction of the anti-CD20 monoclonal antibody rituximab to standard chemotherapy.1,2 Despite the improvement in survival with chemoimmunotherapy, cure has been elusive and the use of cytotoxic therapy is associated with short-term and long-term side-effects.
The Lancet Haematology , commentaire, 2016